In vivo analysis of the role of O-Glycosylations of von Willebrand factor

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Badirou, Idinath ^a   Kurdi, Mohamad ^a   Legendre, Paulette ^a,b   Rayes, Julie ^a   Bryckaert, Marijke ^a,b   Casari, Caterina ^a   Lenting, Peter J ^a,b   Christophe, Olivier D ^a,b   Denis, Cecile V ^a,b  

^a Dept Environ Med Natl Inst Publ HIth   (Norway)

^b UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; PEANUT AGGLUTININ; VON WILLEBRAND FACTOR; DIAGNOSTIC AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOSYNTHESIS; BLEEDING TIME; BLOOD LEVEL; CONTROLLED STUDY; GENE MUTATION; HYDRODYNAMICS; IN VIVO STUDY; LIVER CELL; MOUSE; NONHUMAN; PROTEIN GLYCOSYLATION; THROMBOCYTE ADHESION; THROMBOGENESIS; ANIMAL; CELL STRAIN COS1; CERCOPITHECUS; GENETICS; GLYCOSYLATION; HALF LIFE TIME; METABOLISM; MUTATION; PROTEIN MULTIMERIZATION; THROMBOSIS; VON WILLEBRAND DISEASE;

ARACHIS HYPOGAEA; MURINAE; MUS;

ANIMALS; BLEEDING TIME; CERCOPITHECUS AETHIOPS; COS CELLS; GLYCOSYLATION; HALF-LIFE; MICE; MUTATION; PEANUT AGGLUTININ; PROTEIN MULTIMERIZATION; THROMBOSIS; VON WILLEBRAND DISEASES; VON WILLEBRAND FACTOR;

EID: 84861312468     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037508     Document Type: Article

References (34)

1. Sakariassen KS, Bolhuis PA, Sixma JJ, (1979) Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium. Nature 279: 636-638.
2. Weiss HJ, Sussman, II, Hoyer LW, (1977) Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease. J Clin Invest 60: 390-404.
3. Ruggeri ZM, (2003) Von Willebrand factor. Curr Opin Hematol 10: 142-149.
4. Titani K, Kumar S, Takio K, Ericsson LH, Wade RD, et al. (1986) Amino acid sequence of human von Willebrand factor. Biochemistry 25: 3171-3184.
5. Rademacher TW, Parekh RB, Dwek RA, (1988) Glycobiology. Annu Rev Biochem 57: 785-838.
6. Varki A, (1993) Biological roles of oligosaccharides: all of the theories are correct. Glycobiology 3: 97-130.
7. Varki A, Freeze HH, Manzi AE, (2009) Overview of glycoconjugate analysis. Curr Protoc Protein Sci Chapter 12: Unit 12 11 12 11 11-18.
8. Wagner DD, Mayadas T, Marder VJ, (1986) Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factor. J Cell Biol 102: 1320-1324.
9. McKinnon TA, Goode EC, Birdsey GM, Nowak AA, Chan AC, et al. (2010) Specific N-linked glycosylation sites modulate synthesis and secretion of von Willebrand factor. Blood 116: 640-648.
10. Davies JA, Collins PW, Hathaway LS, Bowen DJ, (2008) von Willebrand factor: evidence for variable clearance in vivo according to Y/C1584 phenotype and ABO blood group. J Thromb Haemost 6: 97-103.
11. McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA, (2008) N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood 111: 3042-3049.
12. Canis K, McKinnon TA, Nowak A, Panico M, Morris HR, et al. (2010) The plasma von Willebrand factor O-glycome comprises a surprising variety of structures including ABH antigens and disialosyl motifs. J Thromb Haemost 8: 137-145.
13. van Schooten CJ, Denis CV, Lisman T, Eikenboom JC, Leebeek FW, et al. (2007) Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. Blood 109: 2430-2437.
14. Carew JA, Quinn SM, Stoddart JH, Lynch DC, (1992) O-linked carbohydrate of recombinant von Willebrand factor influences ristocetin-induced binding to platelet glycoprotein 1b. J Clin Invest 90: 2258-2267.
15. Schulte am Esch J 2nd, Robson SC, Knoefel WT, Eisenberger CF, Peiper M, et al. (2005) Impact of O-linked glycosylation of the VWF-A1-domain flanking regions on platelet interaction. Br J Haematol 128: 82-90.
16. Julenius K, Molgaard A, Gupta R, Brunak S, (2005) Prediction, conservation analysis, and structural characterization of mammalian mucin-type O-glycosylation sites. Glycobiology 15: 153-164.
17. Rayes J, Hollestelle MJ, Legendre P, Marx I, de Groot PG, et al. (2010) Mutation and ADAMTS13-dependent modulation of disease severity in a mouse model for von Willebrand disease type 2B. Blood 115: 4870-4877.
18. Palmiter RD, Behringer RR, Quaife CJ, Maxwell F, Maxwell IH, et al. (1987) Cell lineage ablation in transgenic mice by cell-specific expression of a toxin gene. Cell 50: 435-443.
19. Lenting PJ, Westein E, Terraube V, Ribba AS, Huizinga EG, et al. (2004) An experimental model to study the in vivo survival of von Willebrand factor. Basic aspects and application to the R1205H mutation. J Biol Chem 279: 12102-12109.
20. Mohlke KL, Purkayastha AA, Westrick RJ, Smith PL, Petryniak B, et al. (1999) Mvwf, a dominant modifier of murine von Willebrand factor, results from altered lineage-specific expression of a glycosyltransferase. Cell 96: 111-120.
21. Obert B, Tout H, Veyradier A, Fressinaud E, Meyer D, et al. (1999) Estimation of the von Willebrand factor-cleaving protease in plasma using monoclonal antibodies to vWF. Thromb Haemost 82: 1382-1385.
22. Kauskot A, Adam F, Mazharian A, Ajzenberg N, Berrou E, et al. (2007) Involvement of the mitogen-activated protein kinase c-Jun NH2-terminal kinase 1 in thrombus formation. J Biol Chem 282: 31990-31999.
23. Samor B, Michalski JC, Mazurier C, Goudemand M, De Waard P, et al. (1989) Primary structure of the major O-glycosidically linked carbohydrate unit of human von Willebrand factor. Glycoconj J 6: 263-270.
24. Marx I, Christophe OD, Lenting PJ, Rupin A, Vallez MO, et al. (2008) Altered thrombus formation in von Willebrand factor-deficient mice expressing von Willebrand factor variants with defective binding to collagen or GPIIbIIIa. Blood 112: 603-609.
25. Marx I, Lenting PJ, Adler T, Pendu R, Christophe OD, et al. (2008) Correction of bleeding symptoms in von Willebrand factor-deficient mice by liver-expressed von Willebrand factor mutants. Arterioscler Thromb Vasc Biol 28: 419-424.
26. Chitta MS, Duhe RJ, Kermode JC, (2007) Cloning of the cDNA for murine von Willebrand factor and identification of orthologous genes reveals the extent of conservation among diverse species. Platelets 18: 182-198.
27. Stoddart JH Jr, Andersen J, Lynch DC, (1996) Clearance of normal and type 2A von Willebrand factor in the rat. Blood 88: 1692-1699.
28. Turecek PL, Mitterer A, Matthiessen HP, Gritsch H, Varadi K, et al. (2009) Development of a plasma- and albumin-free recombinant von Willebrand factor. Hamostaseologie 29 (Suppl 1): S32-38.
29. Ulrichts H, Udvardy M, Lenting PJ, Pareyn I, Vandeputte N, et al. (2006) Shielding of the A1 domain by the D'D3 domains of von Willebrand factor modulates its interaction with platelet glycoprotein Ib-IX-V. J Biol Chem 281: 4699-4707.
30. Martin C, Morales LD, Cruz MA, (2007) Purified A2 domain of von Willebrand factor binds to the active conformation of von Willebrand factor and blocks the interaction with platelet glycoprotein Ibalpha. J Thromb Haemost 5: 1363-1370.
31. Cruz MA, Handin RI, Wise RJ, (1993) The interaction of the von Willebrand factor-A1 domain with platelet glycoprotein Ib/IX. The role of glycosylation and disulfide bonding in a monomeric recombinant A1 domain protein. J Biol Chem 268: 21238-21245.
32. Plaimauer B, Fuhrmann J, Mohr G, Wernhart W, Bruno K, et al. (2006) Modulation of ADAMTS13 secretion and specific activity by a combination of common amino acid polymorphisms and a missense mutation. Blood 107: 118-125.
33. Yang L, Manithody C, Rezaie AR, (2009) Functional role of O-linked and N-linked glycosylation sites present on the activation peptide of factor X. J Thromb Haemost 7: 1696-1702.
34. Auwerx J, Francois KO, Covens K, Van Laethem K, Balzarini J, (2008) Glycan deletions in the HIV-1 gp120 V1/V2 domain compromise viral infectivity, sensitize the mutant virus strains to carbohydrate-binding agents and represent a specific target for therapeutic intervention. Virology 382: 10-19.